



Benjamin Ebert, MD, PhD

Professor of Medicine, *Harvard Medical School*; Chair of Medical Oncology, *Dana-Farber Cancer Institute*


Dr. Ebert's research focuses on the genetics, biology and therapy of myeloid malignancies. He is the President of the American Society for Clinical Investigation and an elected member of the Association of American Physicians.



Ronald Levy, MD

Summy Professor of Medicine and Program Leader for Lymphoma, *Stanford University School of Medicine*

Dr. Levy has been a leading researcher focusing on monoclonal antibodies and the study of malignant lymphoma for over 25 years. He was the first to successfully treat cancer with a monoclonal antibody and went on to help develop rituximab (Rituxan®) for the treatment of lymphomas.



Valerie Fiordilino Maslow, PA-C

Hematology/Oncology Physician Assistant, *Cancer Center of South Florida*; Multiple sclerosis patient benefiting from a leukemia therapy

Valerie Fiordilino Maslow sits on the Board of Trustees for the Palm Beach chapter of The Leukemia & Lymphoma Society and has received national accolades for her fundraising efforts in honor of her father, who passed away from chronic lymphocytic leukemia at the age of 59. She has since committed her career and life to advocacy, fundraising and research for blood cancers.



**INNOVATIONS IN
RESEARCH:
BLOOD CANCERS
AND BEYOND**



Ron Winslow – Moderator

Former Deputy Bureau Chief, Health and Science, *The Wall Street Journal* (@ronwinslow)


Ron Winslow recently retired from *The Wall Street Journal* after serving as a reporter and editor for nearly 34 years. He has covered the emergence of precision medicine and immuno-oncology as transformative cancer treatments and other developments in the healthcare industry.



Erkut Bahceci, MD

Vice President, Medical Sciences-Hematology, *Astellas Pharma*

Dr. Erkut Bahceci, who previously led Astellas' hematologic malignancies program as the Executive Medical Director of Oncology Medical Sciences, has published numerous papers on acute myeloid leukemia. Dr. Bahceci is a member of both the American Society of Medical Oncology and the American Society of Hematology.



John Byrd, MD

D. Warren Brown Chair, Leukemia Research, *The Ohio State University Comprehensive Cancer Center*

Dr. John Byrd is an internationally known researcher and clinical specialist in leukemia and other hematologic malignancies. He is one of the principals and Chief Medical Officer on the Beat AML Master Clinical Trial.



Brian Druker, MD

Director, *OHSU Knight Cancer Institute*;
Investigator, *Howard Hughes Medical Institute*

Dr. Brian Druker's research is focused on translating the knowledge of the molecular pathogenesis of cancer into specific therapies and investigating the optimal use of these molecularly targeted agents. His work developing imatinib (Gleevec®) for chronic myeloid leukemia (CML) is credited with significantly increasing the life expectancy of patients with CML.



Ann Farrell, MD

Division Director, Hematology Products, Office of Hematology and Oncology Products, Office of New Drugs, *Center for Drug Evaluation and Research, U.S. Food and Drug Administration*

Dr. Ann Farrell's division of the FDA is responsible for the pre-market and post-market portfolio of small molecule and biologic products for a diverse group of hematologic diseases. She has published numerous papers and co-authored chapters on drug development.



Marina Konopleva, MD, PhD

Chief, Leukemia Biology Research, Professor, Department of Leukemia, *The University of Texas MD Anderson Cancer Center*

Dr. Marina Konopleva's laboratory is focused on studying novel agents in acute myeloid and lymphocytic leukemias, with a concentration on BCL-2 targeting and agents targeting leukemic microenvironment and metabolism.



Kimberly Stegmaier, MD

Associate Professor of Pediatrics, *Harvard Medical School*;
Ted Williams Chair, *Dana-Farber Cancer Institute*


Dr. Kimberly Stegmaier has advanced the application of genomics to drug and protein target discovery for the acute leukemias and other pediatric cancers. Multiple clinical trials have resulted from her laboratory's research, including for patients with acute myeloid leukemia.



John Torres, MD – Moderator

Medical Correspondent, *NBC News, MSNBC* (@drjohntorres)

Dr. John Torres is a renowned emergency room physician who has extensive international experience in the field and on the front lines. His reporting covers a wide range of health-related issues across all of NBC's broadcast, cable and digital platforms.



Selina Chen-Kiang, PhD

Professor of Pathology and Laboratory Medicine, Immunobiology and Microbial Pathogenesis, *Weill Cornell Medicine*

Dr. Selina Chen-Kiang is a renowned leader in discerning cell cycle control of immunity and translating discoveries in basic science into innovative cancer therapy. For her insights and seminal contributions to the development of the first effective CDK4/6 therapy, Dr. Chen-Kiang is credited for resurrecting "a cancer drug that almost wasn't" in *Science*.



Louis DeGennaro, PhD

President and Chief Executive Officer, *The Leukemia & Lymphoma Society* (@LouisJDeGennaro)

Dr. Louis DeGennaro leads the operations of The Leukemia & Lymphoma Society, a \$300 million cancer patient advocacy agency. He has been a member of the LLS executive leadership team since he joined LLS as Chief Scientific Officer in 2005 and pioneered LLS's Therapy Acceleration Program®.